Drug Trial Radar · NCT05669430
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
365
Planned (sponsor's estimate)
Start
Mar 23, 2023
Primary completion
Dec 15, 2026
Study completion Sep 5, 2027
Sponsor
- Lead sponsor
- GV20 TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Conditions
- Solid Tumor, Adult
- Refractory Cancer
- Endometrial Carcinoma (EC)
- Squamous Head and Neck Carcinoma
- pMMR/MSS Adenocarcinoma of the Colon or Rectum
- Cutaneous Melanoma
- Non-Small Cell Lung Cancer
Interventions
GV20-0251Biological
Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.
GV20-0251Biological
GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.
GV20-0251 and Pembrolizumab [KEYTRUDA®]Biological
GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
GV20-0251 and Pembrolizumab [KEYTRUDA®]Biological
GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate ORR per RECIST version 1.1 (Parts B and D)Time frame: 12 months
- Percentage of Participants With Adverse Events (Parts A and C)Time frame: 12 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California · Recruiting
HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Not yet recruiting
Yale University
New Haven, Connecticut · Recruiting
Florida Cancer Specialists & Research Institute, LLC
Fort Myers, Florida · Not yet recruiting
Community Health Network, Inc.
Indianapolis, Indiana · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
Detroit, Michigan · Recruiting
NYU Langone Health
New York, New York · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Verdi Oncology Tennessee, Scri Oncology Partners
Nashville, Tennessee · Not yet recruiting
Oncology Consultants, P.A.
Houston, Texas · Recruiting
The University of Texas M. D. Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.